Clinical trials: Healthy Patients
Burns
Evaluation Of Linezolid Pk Profile In Burns Patients
Evaluation of linezolid pk profile in burns patients
- Trial name
- NCT00255996
- Testing
- linezolid
- Where
- 3 sites in France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma
This is a first in human clinical study. Part 1 of the clinical study will assess the safety and tolerability, as well as the single dose pharmacokinetics (PK), of inhaled AZD4604 in healthy volunteers (Part 1a, single ascending…
- Trial name
- NCT04769869
- Testing
- AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients
- Trial name
- NCT04369846
- Testing
- GM-XANTHO onitment
- Where
- 4 sites in Taiwan
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Xantho Biotechnology Co., LTD
C3 Glomerulopathy (C3G), Healthy Adult Participants
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy
This study is the first time the new medicine CPV-104 is being tested in people. CPV-104 is designed to regulate the complement system, which can be overactive in diseases such as C3 glomerulopathy (C3G), an ultra-rare kidney…
- Trial name
- Essential One (NCT07483827)
- Testing
- CPV-104
- Where
- 17 sites in Austria, Belgium and 10 more
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- eleva GmbH
Renal Failure, Chronic, End-Stage Renal Disease
PK of Serelaxin in Severe Renal Impairment and ESRD
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD)…
- Trial name
- CRLX030A2102 (NCT01875523)
- Testing
- Serelaxin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Urea Cycle Disorders, Inborn, Urea Cycle Disorders
Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD
Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2).
- Conditions
- Urea Cycle Disorders, Inborn, Urea Cycle Disorders, Ornithine Transcarbamylase (OTC) Deficiency, Arginase 1 Deficiency
- Trial name
- ANCHOR (NCT07773246)
- Testing
- KRRO-121
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Korro Bio, Inc.
Neoplasm
Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
This study is a visual assessment of diagnostic PET/CT images obtained after a single intravenous injection of BAY85-8050 in patients with cancer
- Trial name
- NCT00961831
- Testing
- F-18 (BAY85-8050)
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatitis C
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate.
- Trial name
- NCT00229749
- Testing
- AVI-4065 Injection
- Volunteers
- 80 people
- Sponsor
- Sarepta Therapeutics, Inc.
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Hypercholesterolemia, LDL Cholesterol
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
- Trial name
- NCT01859455
- Testing
- LGT209 50 mg, LGT209 300 mg, Statins (atorvastatin or simvastatin)
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
COPD
Comparing Pressure Based and Dilution Based Total Lung Capacity Measurements in COPD Patients for Lung Function Diagnostics
Total Lung Capacity (TLC) of the lungs can be determined using a pressure based method (i.e. by body plethysmography) or it can be determined using a dilution based method (i.e.
- Trial name
- NCT04531293
- Testing
- Respiratory Analysis System
- Where
- Switzerland
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ndd Medizintechnik AG
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid…
- Trial name
- NCT02089087
- Testing
- CFZ533
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization
First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients
The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and…
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization, Bacterial Infections
- Trial name
- NCT07708116
- Testing
- CTX-187
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centauri Therapeutics Limited
Chronic Hepatitis b
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects
The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS9950.
- Trial name
- NCT04464733
- Testing
- HRS9950
- Where
- China
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Asthma
Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01743768
- Testing
- SB010
- Where
- 7 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Moderate to Severe Postoperative Pain
A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants
The study is being conducted to evaluate the safety and pharmacokinetic characteristics of SHR8554 injection in subjects with renal insufficiency and healthy subjects.
- Trial name
- NCT07189962
- Testing
- SHR8554 Injection
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteers, Osteoarthritis
Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain
This is a first-in-human, phase 1, single centre, placebo-controlled, double-blind, single ascending dose study of LEVI-04 in heathy volunteers and osteoarthritis patients (with pain attributed to osteoarthritis of the knee)
- Trial name
- NCT03227796
- Testing
- LEVI-04
- Where
- 2 sites in United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Levicept